Peter DeMuth
Chief Tech/Sci/R&D Officer at ELICIO THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
Peter DeMuth is currently the Chief Scientific Officer at Elicio Therapeutics, Inc. He started this position in 2022.
He holds a doctorate degree from the Massachusetts Institute of Technology, which he received in 2013.
He also has an undergraduate degree from the University of Maryland, which he obtained in 2008.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 2024-01-31 | 0 ( -.--% ) | - $ | 2024-04-29 |
Peter DeMuth active positions
| Companies | Position | Start |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-12-31 |
Former positions of Peter DeMuth
| Companies | Position | End |
|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2023-05-31 |
Training of Peter DeMuth
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Peter DeMuth
